Akums Drugs Allots Most IPO Funds to Debt, Acquisition Delay Noted

Akums Drugs and Pharmaceuticals Ltd has successfully deployed ₹637.37 crore of its IPO net proceeds as of March 31, 2026, leaving a minimal ₹4.81 crore unspent. The company's allocation strategy prioritized significant debt reduction for both the company and its subsidiaries, alongside bolstering working capital.

Fund Allocation Breakdown

The majority of the capital raised was directed towards strengthening the company's financial base. ₹159.91 crore was used to clear company debt, while subsidiaries utilized an additional ₹227.09 crore for debt repayment. Working capital requirements were met with ₹55.00 crore. Further allocations included ₹27.87 crore dedicated to acquisitions and a substantial ₹167.50 crore for general corporate purposes, signaling progress in leveraging capital for operational and strategic goals.

Investor Perspective: Balance Sheet Strength and Strategic Moves

This detailed update offers investors transparency into the management of IPO capital. It clearly demonstrates a focus on enhancing the balance sheet through debt reduction and ensuring operational liquidity via working capital. The deployment pattern reflects strategic financial planning aimed at long-term stability and growth. However, the noted delay in acquisition initiatives flags potential challenges in executing strategic expansion plans.

The IPO Journey

Akums Drugs, a prominent player in India's contract pharmaceutical manufacturing sector, completed its Initial Public Offering (IPO) in February 2024, raising gross proceeds of approximately ₹680 crore. The IPO's stated objectives were to repay existing debt, strengthen working capital, facilitate strategic acquisitions for inorganic growth, and meet general corporate expenses. This latest report provides a comprehensive look at the utilization of these funds.

Acquisition Timeline Shift Creates Risk

A primary risk identified for investors is the delay in executing inorganic growth initiatives through acquisitions. The company's filing indicates that the utilization of funds for acquisitions has shifted from an originally estimated FY25 timeline to being completed by the end of FY26. This delay could suggest difficulties in identifying suitable acquisition targets, negotiating terms, or finalizing regulatory approvals for strategic buyouts. Investors will closely watch progress on these fronts.

Industry Alignment

Within the pharmaceutical contract manufacturing space, companies such as Divi's Laboratories, Laurus Labs, Syngene International, and Gland Pharma also emphasize strategic capital allocation for growth and operational efficiency. While these peers manage diverse business models, the emphasis on debt management and strategic investments is a common theme. Akums' approach aligns with industry practices of using IPO funds to deleverage and invest in future growth, though the pace of acquisition execution will be a key differentiator.

Key Figures to Monitor

• Total IPO proceeds utilized by end of FY26: ₹637.37 crore
• Remaining unutilized IPO proceeds: ₹4.81 crore
• Subsidiary debt repayment allocation: ₹227.09 crore

Looking Ahead

Investors should track the allocation of the remaining ₹4.81 crore IPO proceeds. Significant attention should be paid to the progress and timelines for Akums' inorganic growth initiatives and acquisition plans, especially given the previously noted delay. Any further updates on the company's financial health, operational performance, and new product launches will also be crucial for assessing its growth trajectory.